Skip Navigation

Your Environment. Your Health.

About the Tools

In order to determine how myositis patients' illnesses change over time, information is collected from both physicians and patients in a standardized way.

 

Disease activity assesses the manifestations of myositis which are thought to be reversible that result directly from the inflammatory process, whereas disease damage are those persistent changes in anatomy, physiology, pathology or function which result from previously active disease and from complications of therapy or other events.

 

IMACS has developed a consensus on a set of Core Set Domains and Measures for the assessment of disease activity, disease damage and patient-reported outcomes in adult and juvenile myositis patients. They are as follows:

 

Disease Activity Core Set Measures

Physician Global Activity - Visual Analogue Scale/Likert

 

Patient/Parent Global Activity - Visual Analogue Scale/Likert

 

Muscle Strength - Manual Muscle Testing (MMT)

 

Physical Function - Health Assessment Questionnaire (HAQ), Childhood Health Assessment Questionnaire (CHAQ), Childhood Myositis Assessment Scale (CMAS)

 

Laboratory - Muscle enymes

 

Extra-Muscular Activity - Myositis Disease Activity Assessment Tool (MDAAT) [MyoAct, MITAX]

 

Disease Damage Core Set Measures

Myositis Damage Index

 

Physician Global Damage - Visual Analogue Scale/Likert

 

Patient/Parent Global Damage - Visual Analogue Scale/Likert

 

Muscle Strength - MMT

 

Physical Function - [C]HAQ

 

Patient Reported Outcomes

Health Related Quality of Life using SF-36/CHQ, PedsQL

 

Myositis-specific measure to be developed/validated

 

Patient-reported fatigue measures to be developed/validated

 

Reference for Consensus of Core Set Domains and Measures for the assessment of disease activity, disease damage and patient-reported outcomes in adult and juvenile myositis patients


Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheumatology (Oxford), 2001 Nov 40(11):1262-73[Pub Med]

 

Restricted Tool Access

A portion of the IMACS tools are only available via download by registered members of IMACS. Though all users have access to all tool descriptions and references (where applicable), only registered members have access to download the tools themselves and view any educational resources associated with the tool. IMACS members can view these documents and videos by providing their Login Name and Password.

 

Content Types

The tools are available for download in the following media types:

Adobe PDF documents   PDF  

Microsoft Word documents   Default Alt Text  

Flash presentations   Default Alt Text  

 

Preliminary Definitions of Improvement

 

IMACS has also developed and partially validated Preliminary Definitions of Improvement for Adult and Juvenile Myositis which combine these core set measures of disease activity and define clinically meaningful change in each of the core set activity measures. IMACS suggests that these 13 Preliminary Definitions of Improvement be used as outcome measures or endpoints for all therapeutic trials in adult and juvenile myositis.

 

Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FWInternational Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum, 2004 Jul 50(7):2281-90[Pub Med]

Back to Top

Share This Page:

Page Options:

Request Translation Services